Something like

. We'll count words. Let's draft:

President Trump added nine more pharmaceutical companies... So the article has an h2? Actually, the content starts with

. We'll count words. Let's draft:

... So the first element is an h2? Actually, the content is given as:

. We'll count words. Let's draft:

President Trump added nine more pharmaceutical companies... So it seems the article has an h2 heading that is not shown? The content is:

. We'll count words. Let's draft:

... That is weird. Actually, the original content is provided as a string: "

. We'll count words. Let's draft:

President Trump added nine more pharmaceutical companies to his drug-pricing deal on Monday, bringing the total to 26 firms that represent 90% of the domestic market. The combined agreements, struck over the past year, are expected to save Americans more than $600 billion. The news lands as healthcare stocks close out their best quarter yet, with UBS arguing the rally has more room to run.

The expanded pricing framework

..." So the first h2 is actually a placeholder? It says "

. We'll count words. Let's draft:" That is not part of the article. It seems the original content includes some meta-commentary. Actually, the instruction says: "ORIGINAL CONTENT:

. We'll count words. Let's draft:

President Trump added nine more pharmaceutical companies..." So the content includes that phrase. But that is not part of the article. It might be a mistake. We should ignore that and treat the actual article content as starting from the first paragraph. The article has headings: "The expanded pricing framework", "Why UBS sees more upside", "The clinical wins fueling the move". So we need to translate those headings and the paragraphs. We'll extract the actual article content. The original content is:

. We'll count words. Let's draft:

President Trump added nine more pharmaceutical companies to his drug-pricing deal on Monday, bringing the total to 26 firms that represent 90% of the domestic market. The combined agreements, struck over the past year, are expected to save Americans more than $600 billion. The news lands as healthcare stocks close out their best quarter yet, with UBS arguing the rally has more room to run.

The expanded pricing framework

The nine additional firms are mostly midsize drugmakers, including Alcon, Astellas Pharma, and Teva Pharmaceuticals. They pledged $19.6 billion combined toward U.S. manufacturing and agreed to offer their drugs to every state Medicaid program at discounted prices. The White House said 17 companies had already joined the pricing framework over the past year, meaning the latest additions bring the total to 26.

Why UBS sees more upside

UBS's Michael Yee said the advance reflects a stack of major clinical wins and that new pricing deals have calmed fears of a broader industry crackdown. He said pharmaceutical companies are sitting on record cash piles and pushing more into R&D after a multiyear stretch of cheap valuations. Yee added that valuations are still not stretched and Washington's pricing overhang is easing, making the current move look like the start of a longer re-rating.

The clinical wins fueling the move

Merck's melanoma vaccine, developed with Moderna, met its main trial goals in a large trial involving more than 1,100 patients, with results reported on August 19. The FDA approved Revolution Medicines' pancreatic cancer drug daraxonrasib on August 26, which nearly doubled median survival in a late-stage trial compared with chemotherapy. Merck's antibody-drug conjugate sacituzumab tirumotecan posted a positive lung cancer trial readout earlier this year and is now being tested across 17 late-stage studies.

Yee also named Bristol Myers Squibb as a top pick, with UBS carrying a Buy rating and expecting several late-stage trial readouts before year-end. The SPDR S&P Biotech ETF (XBI) has climbed 80% in the last 12 months, a sign of the sector's momentum. Investors will be watching for those Bristol Myers readouts, along with any further additions to the pricing framework.

That's about 300 words? Let's count: first paragraph ~50, second ~60, third ~70, fourth ~70, fifth ~60 = ~310. Need more. We can expand each section with more detail from facts. For example, in the first section, we can mention that the combined deals save $600B, but we already have that in lead. We can also mention that the 26 companies represent 90% of the domestic market, but that's in lead. We can add a sentence about the significance of the Medicaid agreement. Also we can mention that the pricing deal is part of a broader effort to lower drug costs. But we don't have that explicitly. We can say "The agreements are part of a broader push to lower drug prices, with the White House touting the savings." But that's inference. Better to stick to facts. We can add a sentence about the size of the market: "The 26 companies now cover nine out of every ten prescriptions filled in the U.S." But that's an interpretation of 90% of domestic pharmaceutical market. That's okay. We can also add a sentence about the timing: "The announcement came on the same day healthcare stocks posted their best quarter on record." But we don't have "on record" - we have "best quarter yet" - that's fine. We can also add a sentence about the specific drugs: "The melanoma vaccine is a personalized therapy that uses mRNA technology, while daraxonrasib targets a specific mutation in pancreatic cancer." But we don't have that detail. We only have the facts given. So we cannot add that. We can expand on the clinical wins: "The melanoma vaccine, developed with Moderna, met its main trial goals in a large trial involving more than 1,100 patients, with results reported on August 19. The FDA approved Revolution Medicines' pancreatic cancer drug daraxonrasib on August 26, which nearly doubled median survival in a late-stage trial compared with chemotherapy. Merck's antibody-drug conjugate sacituzumab tirumotecan posted a positive lung cancer trial readout earlier this year and is now being tested across 17 late-stage studies." That's already detailed. We can add a sentence about the impact on the sector: "These wins have helped drive the SPDR S&P Biotech ETF up 80% over the past year." But we have that in the last section. We can also add a sentence about the pricing deal's effect on investor sentiment: "Yee said the pricing deals have calmed fears of a broader industry crackdown, which had weighed on the sector for years." That's a paraphrase. We can also add a sentence about the cash piles: "With record cash on hand, companies are investing more in research and development, a shift from the cost-cutting of recent years." That's a paraphrase. We can also add a sentence about the valuation: "Yee said